STK11 and non-small cell lung carcinoma: The antitumor activity of BKM120, a PI3K inhibitor, and AZD2014, an mTORC1/C2 inhibitor, was tested in our 6 NSCLC PDXs with various genetic alterations that activate the PI3K pathway (mutations of PIK3CA, PIK3R1, PTEN, STK11) (Figure 4a).